An unusual survival for 6.5 years with end-stage hepatitis C related advanced liver cirrhosis following sustained virologic response with direct antiviral agents – A case report from A low-resource setting.
Main Article Content
Keywords
Hepatic Encephalopathy, Liver Cirrhosis, Hepatitis C, Decompensated End-stage Liver Disease.
Abstract
Advanced chronic liver disease is frequently complicated by hepatic encephalopathy (HE), hepatorenal syndrome, and spontaneous bacterial peritonitis; predictors of poor prognosis that significantly reduce survival. While orthotopic liver transplantation (OLT) remains the definitive treatment, it is often inaccessible in resource-limited settings. We present the case of a 70-year-old retired hospital attendant with hypertension who developed decompensated liver cirrhosis secondary to chronic hepatitis C virus HCV infection. She presented with portal hypertension, grade 4 HE, hepatorenal syndrome, and spontaneous bacterial peritonitis. She remained in grade 3 to 4 HE for approximately three months and in grade 2–3 HE for an additional two months. Despite profound hepatic decompensation and a high Model for End-Stage Liver Disease-Sodium (MELD-Na) score of 48 (indicating a 71% three-month mortality) and a Child-Pugh score of 15 (Class C), she responded remarkably to intensive conservative management. After six months of inpatient care, which included direct-acting antiviral therapy, anti-failure therapy, and seizure management, she recovered from hepatic coma. She received a six-month course of direct acting antivirals (DAAs), daclatasvir and sofosbuvir and achieved sustained virologic response. Over six and a half
years later, she remains in good health with preserved cognition and normal blood pressure and has been under annual surveillance for hepatocellular carcinoma. This case underscores the transformative potential of DAAs in improving survival even among severely decompensated HCV-related cirrhotic patients. It highlights the need for expanded access and subsidization of DAAs in low-resource settings, where liver transplantation is not feasible, and emphasizes the role of aggressive, supportive management in bridging the treatment gap.
References
2. Chaudhari R, Fouda S, Sainu A, Pappachan JM. Metabolic complications of hepatitis C virus infection. World J Gastroenterol. 2021 Apr 7;27(13):1267-1282. doi: 10.3748/wjg.v27.i13.1267.
3. Samonakis DN, Koulentaki M, Coucoutsi C, Augoustaki A, Baritaki C, Digenakis E, Papiamonis N, Fragaki M, Matrella E, Tzardi M, Kouroumalis EA. Clinical outcomes of compensated and decompensated cirrhosis: A long-term study. World J Hepatol. 2014 Jul 27;6(7):504-12. doi: 10.4254/wjh.v6.i7.504.
4. Ali S, Ur-Rehman T, Ali M, Haque S, Rasheed F, Lougher E, Sarfraz Nawaz M, Paudyal V. (2021). Improving access to the treatment of hepatitis C in low- and middle-income countries: Evaluation of a patient assistance programme. International Journal of Clinical Pharmacy 2021;43:958-968.
5. Rosenthal ES, Graham CS. Price and affordability of direct-acting antiviral regimens for hepatitis C virus in the United States. Infectious Agents and Cancer 2016; 11:24 – 32.
6. Im GY, Dieterich DT. Direct-acting antiviral agents in patients with hepatitis C cirrhosis. Gastroenterol Hepatol (N Y) 2012;8:727–65.
7. Abere S, Oyan B, Alali DJ, Omunakwe H, Ejkem M. Viral hepatitis B and C: Knowledge gaps and patterns of prevalence among medical doctors in Rivers State, Nigeria. Cureus. 2022 Mar 7;14(3):e22928. doi: 10.7759/cureus.22928.
8. Li LX, Lin JS, Tackett S, Bertram A, Sisson SD, Rastegar D, Buresh ME. Closing the Gaps in Hepatitis C Knowledge Among Internal Medicine Residents in the United States. Am J Med Open. 2024 Aug 13;12:100077. doi: 10.1016/j.ajmo.2024.100077.
9. Hadjihambi A, Arias N, Sheikh M, Jalan R. Hepatic encephalopathy: a critical current review. Hepatol Int. 2018 Feb;12(Suppl 1):135-147. doi: 10.1007/s12072-017-9812-3.
10. Patidar KR, Bajaj JS. Covert and overt hepatic encephalopathy: Diagnosis and management. Clin Gastroenterol Hepatol 2015; 13:2048–61.
11. Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, Morgan MY; International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN). Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther. 2011 Apr;33(7):739-47. doi: 10.1111/j.1365-2036.2011.04590. x.
12. Botta F, Giannini E, Romagnoli P, Fasoli A, Malfatti F, Chiarbonello B, Testa E, Risso D, Colla G, Testa R. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut. 2003 Jan;52(1):134-9. doi: 10.1136/gut.52.1.134.
13. Bohra A, Worland T, Hui S, Terbah R, Farrell A, Robertson M. Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care. World J Gastroenterol. 2020 May 14;26(18):2221-2231. doi: 10.3748/wjg. v26.i18.2221.
14. Fabrizi F, Aghemo A, Messa P. Hepatorenal syndrome and novel advances in its management. Kidney Blood Press Res2013; 37:588–601.
15. Allegretti AS, Ortiz G, Wenger J, Deferio JJ, Wibecan J, Kalim S, Tamez H, Chung RT, Karumanchi SA, Thadhani RI. Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study. Int J Nephrol. 2015; 2015:108139. doi: 10.1155/2015/108139. Allegretti AS, Ortiz G, Wenger J, et al. Prognosis of acute kidney injury and hepatorenal syndrome in patients with cirrhosis: A prospective cohort study. Int J Nephro l2015;2015:108139.
16. Pageaux GP, Nzinga CL, Ganne N, Samuel D, Dorival C, Zoulim F, et al. Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis. BMC Infect Dis. 2022 Jan 27;22(1):94. doi: 10.1186/s12879-022-07076-0
17. Chan J, Young J, Cox J, Nitulescu R, Klein MB. Patterns of practice and barriers to care for hepatitis C in the direct-acting antiviral (DAA) era: A national survey of Canadian infectious diseases physicians. Can Liver J. 2018 Dec 25;1(4):231-239. doi: 10.3138/canlivj.2018-0012.
18. Ji F, Wang W, Dang S, Wang S, Li B, Bai D, et al. Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis: A real-world study Dr Stefano Vella. Infect Agent Cancer. 2017 Sep 13;12(1).
19. Ghebremeskel GG, Berhe Solomon M, Achila OO, Mengistu ST, Asmelash RF, Berhane Mesfin A, et al. Real-world treatment outcome of direct-acting antivirals and patient survival rates in chronic hepatitis C virus infection in Eritrea. Sci Rep. 2023 Dec 1;13(1).
20. Guedes TP, Fragoso P, Lemos C, Garrido M, Silva J, Falcão D, et al. Long-Term Follow-Up of Advanced Liver Disease after Sustained Virological Response to Treatment of Hepatitis C with Direct-Acting Antivirals: Outcomes from a Real-World Portuguese Cohort. GE Port J Gastroenterol. 2020 Apr 1;27(3):149–59.
21. Elbahrawy A, Atalla H, Mahmoud AA, Eliwa A, Alsawak A, Alboraie M, et al. Prediction and surveillance of de novo HCC in patients with compensated advanced chronic liver disease after hepatitis C virus eradication with direct antiviral agents. Frontiers in Virology. 2023 Oct 24;3.
22. Wong RJ, Gish RG, Ahmed A. Hepatic encephalopathy is associated with significantly increased mortality among patients awaiting liver transplantation. Liver Transplantation. 2014 Dec 1;20(12):1454–61.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
This is an open-access journal and articles are distributed under the terms of the Creative Commons Attribution Non-Commercial Share-Alike License 4.0. This licence allows users to download and share, remix, tweak and build upon the article for non-commercial purposes, so long as the original authorship is acknowledged and the new creations are licensed under identical terms.
Roland Stephen, Department of Medicine, Modibbo Adama University Teaching Hospital, Yola, Nigeria
School of Doctoral Studies, Faculty of Public Health, Unicaf University, Cyprus